<DOC>
	<DOC>NCT00528242</DOC>
	<brief_summary>To investigate the severity of secondary Raynaud's disease-related attacks during the 14 days 2101 dosing period.</brief_summary>
	<brief_title>Safety, Tolerability, and Pharmacodynamic Profile of Oral 2101 in Secondary Raynaud's Disease</brief_title>
	<detailed_description>1. Number and cumulative duration of Raynaud's attacks. 2. Adverse events and changes in vital signs. 3. SLx-2101 pharmacokinetic parameters derived after dosing on Day 1 and Day maximum plasma concentration (Cmax), area under the plasma concentration-time curve (AUC0-4), time to Cmax (tmax), and accumulation ratio</detailed_description>
	<mesh_term>Raynaud Disease</mesh_term>
	<criteria>male and female ages 18 and 65 y.o. BMI Body weight within a body mass index range of 17 30 kg/m2 (inclusive). Hypersensitivity to the active substance of SLx2101or to any of the excipients. Past or present disease that is judged by the Investigator to have the potential to interfere with the study procedures, compromise safety, or affect the pharmacokinetic and pharmacodynamic evaluations</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>